Phase II study of calcitriol-enhanced docetaxel in patients with previously untreated metastatic or locally advanced pancreatic cancer
Authors:
- 9 October 2008
- journal article
- phase ii-studies
- Published by Springer Nature in Investigational New Drugs
- Vol. 27 (4) , 374-378
Abstract
Purpose: To determine the safety and efficacy of weekly high-dose oral calcitriol and docetaxel, given to patients with non-resectable, incurable pancreatic cancer. Patients and Methods: Twenty-five patients were enrolled onto this phase II study. Patients were treated with oral calcitriol 0.5 μg/kg on day 1, followed by docetaxel 36 mg/m2 IV on day 2, administered weekly for three consecutive weeks, followed by 1 week without treatment. Patients followed a low-calcium diet and increased their hydration. The primary end-point of the trial was time-to-progression. Results: Three of 25 patients attained a partial response (12%, 95% CI 3 to 31) and seven (28%) achieved stable disease. Median time-to-progression was 15 weeks, and median overall survival was 24 weeks. Toxicities observed (hyperglycemia, fatigue) were mostly attributable to the docetaxel or its pre-treatment. Conclusions: This regimen of high-dose calcitriol with docetaxel may have activity in incurable pancreatic cancer, with a modest increase in TTP when compared to historical findings using single-agent docetaxel. However, results do not appear superior to those seen with gemcitabine, with or without erlotinib.Keywords
This publication has 19 references indexed in Scilit:
- A Nested Case-Control Study of Plasma 25-Hydroxyvitamin D Concentrations and Risk of Colorectal CancerJNCI: Journal of the National Cancer Institute, 2007
- Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trialThe American Journal of Clinical Nutrition, 2007
- Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials GroupJournal of Clinical Oncology, 2007
- Double-Blinded Randomized Study of High-Dose Calcitriol Plus Docetaxel Compared With Placebo Plus Docetaxel in Androgen-Independent Prostate Cancer: A Report From the ASCENT InvestigatorsJournal of Clinical Oncology, 2007
- Phase II Study of Gemcitabine in Combination with Docetaxel in Patients with Advanced Pancreatic Carcinoma (E1298)Oncology, 2004
- Phase II Study of Docetaxel in Patients with Pancreatic Cancer Previously Untreated with Cytotoxic ChemotherapyCancer Investigation, 2002
- Weekly high-dose calcitriol and docetaxel in advanced prostate cancerSeminars in Oncology, 2001
- A phase II studyEuropean Journal of Cancer, 2000
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000
- Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937.Genes & Development, 1996